About Cryoniss
Cryoniss is a company based in Macclesfield (United Kingdom) founded in 2018 by Phil Hargreaves and Sonia Houghton was acquired by Biofortuna in May 2024. Cryoniss has raised $683.06 thousand across 1 funding round from investors including Maven Capital Partners and Biofortuna. The company has 9 employees as of March 31, 2022. Cryoniss operates in a competitive market with competitors including GenVault Corporation, iSpecimen, PrecisionMed, AminoChain and ViaCell, among others.
- Headquarter Macclesfield, United Kingdom
- Employees 9 as on 31 Mar, 2022
- Founders Phil Hargreaves, Sonia Houghton
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cryoniss Ltd.
- Date of Incorporation 06 Mar, 2018
- Jurisdiction MACCLESFIELD, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$683.06 K (USD)
in 1 rounds
-
Latest Funding Round
$683.06 K (USD), Seed
Jan 18, 2022
-
Investors
Maven Capital Partners
& 1 more
-
Employee Count
9
as on Mar 31, 2022
-
Acquired by
Biofortuna
(May 10, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Cryoniss
Unlock access to complete
Unlock access to complete
Funding Insights of Cryoniss
Cryoniss has successfully raised a total of $683.06K through 1 strategic funding round. The most recent funding activity was a Seed round of $683.06 thousand completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cryoniss
Cryoniss has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Maven Capital Partners and Biofortuna.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for private equity investments.
|
Locked | Locked | Locked | |
|
Provider of manufacturing services for immunoassays, molecular diagnostics, and regulatory services
|
Locked | Locked | Locked |
Investor details for Cryoniss
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cryoniss
Investment portfolio details for Cryoniss
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cryoniss
Detailed financials for Cryoniss
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cryoniss Comparisons
Peer comparison for Cryoniss
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cryoniss
Cryoniss operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GenVault Corporation, iSpecimen, PrecisionMed, AminoChain and ViaCell, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biosamples are stabilized, transported, stored, and retrieved by GenVault.
|
|
| Locked | Locked | Locked |
Provider of a biorepository of human clinical specimens
|
|
| Locked | Locked | Locked |
Human biological materials for research are supplied via a biorepository.
|
|
| Locked | Locked | Locked |
A blockchain-based platform for tokenizing and incentivizing stem cell donations
|
|
| Locked | Locked | Locked |
Provider of services for collecting and preserving umbilical cord blood stem cells
|
Detailed competitors of Cryoniss
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cryoniss
Complete news archive for Cryoniss
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cryoniss
Cryoniss was founded in 2018 and raised its 1st funding round 4 years after it was founded.
Cryoniss is headquartered in Macclesfield, United Kingdom. It is registered at Macclesfield, Cheshire, United Kingdom.
Sonia Houghton is the current CEO of Cryoniss. They have also founded this company.
Cryoniss is a funded company, having raised a total of $683.06K across 1 funding round to date.
As of Mar 31, 2022, the latest employee count at Cryoniss is 9.
Cryoniss was established in 2018 in Macclesfield, United Kingdom, as a provider of biobanking services within the life sciences sector. Human biological samples are stored in vapor-phase liquid nitrogen or at ambient temperatures. Clinical samples from various trial phases are accommodated, along with bioreagents such as glycerol stocks, DNA, frozen cultures, and antibodies maintained at ambient conditions. Operations focus on secure preservation for research and development needs.
Cryoniss's top competitors include iSpecimen, AminoChain and GenVault Corporation.
Cryoniss has 2 investors. Key investors include Maven Capital Partners, and Biofortuna.